• 1\. Patients with head and neck squamous cell carcinoma diagnosed by histology or cytology;

• 2\. Have not received systematic treatment for head and neck squamous cell carcinoma in the past;

• 3\. According to the AJCC TNM staging system, it is divided into stages III-IVB;

• 4\. ECOG score: 0-1 point;

• 5\. Expected survival period ≥ 12 weeks;

• 6\. The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 109/L (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 109/L, hemoglobin ≥ 90g/L; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml/min/1.73 m2 (calculated according to the Cockcroft Gault formula);

• 7\. Female subjects with fertility, as well as male subjects with partners who are fertility women, are required to use a medically approved contraceptive measure (such as intrauterine device, contraceptive pill, or condom) during the study treatment period, at least 6 months after the last use of adebelimab, and at least 6 months after the last use of chemotherapy;

• 8\. Voluntarily join this study, sign the informed consent form, have good compliance, and cooperate with follow-up.